Mai Elaarag

Mai Elaarag

Auto-generated profile, based on publicly available information

Mai Elaarag

Surgical Research Section, Department of Surgery Hamad Medical Corporation Doha Qatar

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MAMothana K. Al-Omari
Mothana K. Al-Omari
MEMai Elaarag
Mai Elaarag
ASAlrayyan Private school
Alrayyan Private school
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
AZAyman A. Zarour
Ayman A. Zarour
AAAbdulla A. Al-Ansari
Abdulla A. Al-Ansari
Boronic acids/esters have recently emerged in the field of medicinal and pharmaceutical research due to their exceptional oxophilicity, low toxicity, and unique structure. They are known as potent enzyme inhibitors, cancer therapy capture agents, and can mimic certain types of antibodies to fight infections. They have been designed and developed into drugs, and this approach has emerged in the last 20 years. Five boronic acid drugs have been approved by the FDA and Health Canada, two of which are used to treat cancer, specifically multiple myeloma. The purpose of this review is to investigate boronic acid/ester derivatives as potential pharmaceutical agents as well as the mechanism of action. It will concentrate on six types of cancer: multiple myeloma, prostate cancer, breast cancer, lung cancer, cervical cancer, and colon cancer. Some newly developed boron-containing compounds have already demonstrated highly promising activities, but further investigation is required before final conclusions can be drawn.

19 February 2025 in Health Science Reports
Verified
Journal Article
Open access
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
ZFZainab E. Fares
Zainab E. Fares
MEMai Elaarag
Mai Elaarag
MOMaha Osman
Maha Osman
ASAlrayyan Private school
Alrayyan Private school
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
Background and Aims: Artificial intelligence (AI) has become integral to medical research, impacting various aspects such as data analysis, writing assistance, and publishing. This paper explores the multifaceted influence of AI on the process of writing medical research papers, encompassing data analysis, ethical considerations, writing assistance, and publishing efficiency.Methods: The review was conducted following the PRISMA guidelines; a comprehensive search was performed in Scopus, PubMed, EMBASE, and MEDLINE databases for research publications on artificial intelligence in medical research published up to October 2023.Results: AI facilitates the writing process by generating drafts, offering grammar and style suggestions, and enhancing manuscript quality through advanced models like ChatGPT. Ethical concerns regarding content ownership and potential biases in AI‐generated content underscore the need for collaborative efforts among researchers, publishers, and AI creators to establish ethical standards. Moreover, AI significantly influences data analysis in healthcare, optimizing outcomes and patient care, particularly in fields such as obstetrics and gynecology and pharmaceutical research. The application of AI in publishing, ranging from peer review to manuscript quality control and journal matching, underscores its potential to streamline and enhance the entire research and publication process. Overall, while AI presents substantial benefits, ongoing research, and ethical guidelines are essential for its responsible integration into the evolving landscape of medical research and publishing.Conclusion: The integration of AI in medical research has revolutionized efficiency and innovation, impacting data analysis, writing assistance, publishing, and others. While AI tools offer significant benefits, ethical considerations such as biases and content ownership must be addressed. Ongoing research and collaborative efforts are crucial to ensure responsible and transparent AI implementation in the dynamic landscape of medical research and publishing.

15 December 2022 in Health Science Reports
Verified
Journal Article
Open access
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
MDMohamed B. Al Darwish
Mohamed B. Al Darwish
MEMai Elaarag
Mai Elaarag
ASAlrayyan Private school
Alrayyan Private school
MRMohamed Amine Rejeb
Mohamed Amine Rejeb
AAAbdulla A. Al‐Ansari
Abdulla A. Al‐Ansari
Background and Aims: On March 11, 2020, the WHO has declared COVID‐19 a global pandemic, affecting our day‐to‐day lives. Physical distancing and lockdown made significant obstacles to populations, particularly healthcare systems. Most healthcare workers were reallocated to COVID‐19 facilities. Noncommunicable disease patients were given low priority and are at a higher risk of severe COVID‐19 infection, which disrupted the treatment and disease management of these patients. This review aimed to assess the effect of COVID‐19 on different types of noncommunicable diseases and the severity it may cause to patients.Methods: We have conducted a review of the literature on COVID‐19 and noncommunicable diseases from December 2019 until January 2022. The search was done in PubMed and Cochrane for relevant articles using variety of searching terms. Data for study variables were extracted. At the end of the selection process, 46 papers were selected for inclusion in the literature review.Result: The result from this review found that the COVID‐19 pandemic has affected the efficiency of the patient's treatment indirectly by either delaying or canceling sessions, which solidified the need to rely more on telemedicine, virtual visits, and in‐home visits to improve patient education and minimize the risk of exposure to the patients. The major and most common types of noncommunicable diseases are known to be related to the severe outcomes of COVID‐19 infection. It is strongly recommended to prioritize these patients for vaccinations against COVID‐19 to provide them with the protection that will neutralize the risk imposed by their comorbidities.Conclusion: We recommend conducting more studies with larger population samples to further understand the role of noncommunicable diseases (NCDs) in this pandemic. However, this pandemic has also affected the efficiency of NCDs treatment indirectly by delaying or canceling sessions and others.

15 June 2023 in Journal of Epidemiology and Global Health
Verified
Journal Article
Open access
PDF file
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
AAAyisha Ameen
Ayisha Ameen
DSDoaa M. Sabir
Doaa M. Sabir
HAHeba Alkharraz
Heba Alkharraz
MEMai Elaarag
Mai Elaarag
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
Background and Aim: The impact of multiple risk factors on COVID-19 mortality has been previously reported in multiple systematic reviews and meta-analyses. The aim of this review is to provide a comprehensive update on the association between hypertension (HTN) and mortality in patients with COVID-19. Methods: A systematic review and meta-analysis were performed and followed the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. A search was achieved using PubMed, Scopus, and Cochrane Databases for research publications on hypertension, COVID-19, and mortality published between December 2019 and August 2022. Results: A total of 23 observational studies involving 611,522 patients from 5 countries (China, Korea, the UK, Australia, and the USA) were included in our study. The confirmed number of COVID-19 with HTN cases in each study ranged from 5 to 9964. The mortality ranged from 0.17% to 31% in different studies. Pooled results show that the mortality rate of COVID-19 among the included studies ranges from a minimum of 0.39 (95% CI 0.13–1.12) to a maximum of 5.74 (95% CI 3.77–8.74). Out of the 611,522 patients, 3119 died which resulted in an overall mortality prevalence of 0.5%. Subgroup analyses indicated that patients with COVID-19 who have hypertension and male patients had slightly less risk of mortality than female patients [the percentage of men > 50%; OR 1.33: 95% CI (1.01, 1.76); the percentage of men ≤ 50%: OR 2.26; and 95% CI (1.15, 4.48)]. Meta-regression analysis results also showed a statistically significant association between hypertension and COVID-19 mortality. Conclusion: This systematic review and meta-analysis suggest that hypertension may not be the only risk factor associated with the increased mortality rate during the COVID-19 pandemic. In addition, a combination of other comorbidities and old age appears to increase the risk of mortality from COVID-19. Graphical

5 September 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ASAlrayyan Private school
Alrayyan Private school
KGKhalil Garada
Khalil Garada
RHReem Al Huneidi
Reem Al Huneidi
ZBZaid M.H. Baddar
Zaid M.H. Baddar
AZAyman A. Zarour
Ayman A. Zarour
KAKhalid Alrumaihi
Khalid Alrumaihi
Ataxia-telangiectasia mutated (ATM) kinase plays a pivotal role in the cellular response to DNA damage. Under normal conditions, ATM acts as a tumor suppressor by regulating pathways that lead to apoptosis and cell cycle arrest via effectors like p53, p21, CHK1, and CHK2. Paradoxically, in some cancers, ATM promotes tumor cell survival and metastasis, especially when aberrantly activated, linking it to therapy resistance and poor outcomes. Its involvement in both radiotherapy and chemotherapy has made ATM an attractive target for cancer treatment. Inhibitors such as KU-55933, KU-60019, and AZD1390 have shown the potential to sensitize cancer cells to radiotherapy by impairing DNA repair, thereby enhancing treatment efficacy. A key challenge remains the development of ATM inhibitors that can effectively cross the blood-brain barrier for use against brain tumors. Currently, none have gained approval from the FDA or EMA, but six candidates, AZD1390, AZD0156, ZN-B-2262, SYH2051, WSD0628 and M3541 are in clinical trials, often as adjuncts to radiotherapy or in combination with PARP inhibitors. Their safety and effectiveness, however, are still under investigation. This review synthesizes ATM's dual roles and the therapeutic promise of targeting ATM in cancer radiotherapy.

28 June 2022 in Arab Journal of Urology
Verified
Journal Article
Open access
MEMai Elaarag
Mai Elaarag
HAHind Alashi
Hind Alashi
MAMaya Aldeeb
Maya Aldeeb
IKIbrahim Khalil
Ibrahim Khalil
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
A UPJO is a blockage of the ureter that affects urine flow. UPJO is mainly treated by an open approach, however, in recent years minimally invasive techniques are taking place. These techniques inc...